ArticleScientific reports2025
Hyperimmune serum containing Histophilus somni rHsp60, rOMP40 and Actinobacillus pleuropneumoniae LPS antibodies as supplementary treatment for calf respiratory diseases.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bovine respiratory disease (BRD) in dairy heifer calves cause significant economic losses associated with treatment costs, reduced growth rate and mortality. Bovine hyperimmune serum was produced in cows hyperimmunized with three conserved antigens (Histophilus somni rHsp60, H. somni rOMP40, and Actinobacillus pleuropneumoniae LPS core oligosaccharide), which exhibit broad cross-reactivity with several Gram-negative bacteria. Dairy heifer calves received serum subcutaneously on the first day of treatment for BRD, as an additive to antibiotics and anti-inflammatory drugs. Health status was estimated on a modified point scale system on days 1, 7 and 14th of the treatment. The calves were divided into four groups (10 per group): two with moderate signs of BRD, one with and one without hyperimmune serum application, and two with severe signs of BRD, one receiving hyperimmune serum. At day 1,7,14 of treatment and day 180 of age, plasma fibrinogen, serum haptoglobin, serum amyloid A, IgG
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.